Treatment of Candida Infections with Amphotericin B Lipid Complex
The efficacy and renal safety of amphotericin B lipid complex (ABLC) were assessed in >900 patients with candidiasis. Overall, a favorable clinical response (cured or improved) was observed in 61% of patients infected with Candida species only, in 62% of patients infected with C. albicans, and in...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2005-05, Vol.40 (Supplement-6), p.S384-S391 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S391 |
|---|---|
| container_issue | Supplement-6 |
| container_start_page | S384 |
| container_title | Clinical infectious diseases |
| container_volume | 40 |
| creator | Ito, James I. Hooshmand-Rad, Roya |
| description | The efficacy and renal safety of amphotericin B lipid complex (ABLC) were assessed in >900 patients with candidiasis. Overall, a favorable clinical response (cured or improved) was observed in 61% of patients infected with Candida species only, in 62% of patients infected with C. albicans, and in 61% of patients infected with a non-albicans Candida species. Clinical responses were similar in patients infected with invasive C. albicans and non-albicans Candida species (63% and 62%, respectively). Similarly, response rates of 60% and 59% were observed in patients infected with noninvasive C. albicans and non-albicans Candida species, respectively. Compared with patients who received lower doses of ABLC, patients who required higher doses of ABLC because of more-virulent infections did not demonstrate significant renal impairment, as assessed by end-of-therapy changes in serum creatinine level from baseline (median, 0.1 mg/dL; range, -3.9 to 2.4 mg/dL), incidence of serum creatinine doubling (16%), and need for new dialysis (7%). These data indicate the safety and efficacy of ABLC in treating candidiasis. |
| doi_str_mv | 10.1086/429330 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67701953</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4484195</jstor_id><sourcerecordid>4484195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-97b802a1d92fcb33d147c88a19c4e7dfe54ab65a02d2fc9f60776585f5bda8dc3</originalsourceid><addsrcrecordid>eNqFkE1LxDAYhIMofqz6C0SKB2_VpEma5LgWPxYWRFhRvIQ0STHrtqlJFtd_b2UXBS-e3oF5GN4ZAI4RvECQl5ekEBjDLbCPKGZ5SQXaHjSkPCcc8z1wEOMcQoQ4pLtgD1EOhSjIPhjPglWptV3KfJNVqjPOqGzSNVYn57uYfbj0mo3b_tUnG5x2XXaVTV3vTFb5tl_Y1SHYadQi2qPNHYHHm-tZdZdP728n1Xiaa1KUKRes5rBQyIii0TXGBhGmOVdIaGKZaSwlqi6pgoUZANGUkLGSctrQ2ihuNB6B83VuH_z70sYkWxe1XSxUZ_0yypIxiATF_4KIUcgFFQN49gec-2XohhKyQEIQTjn5TdPBxxhsI_vgWhU-JYLye3q5nn4ATzdpy7q15hfbbD0AJ2tgHpMPPz4hnHz_PQL52nYx2dWPrcLbUA0zKu-eXySpHm5Lip7lE_4Cl8OUQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219948584</pqid></control><display><type>article</type><title>Treatment of Candida Infections with Amphotericin B Lipid Complex</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ito, James I. ; Hooshmand-Rad, Roya</creator><creatorcontrib>Ito, James I. ; Hooshmand-Rad, Roya</creatorcontrib><description>The efficacy and renal safety of amphotericin B lipid complex (ABLC) were assessed in >900 patients with candidiasis. Overall, a favorable clinical response (cured or improved) was observed in 61% of patients infected with Candida species only, in 62% of patients infected with C. albicans, and in 61% of patients infected with a non-albicans Candida species. Clinical responses were similar in patients infected with invasive C. albicans and non-albicans Candida species (63% and 62%, respectively). Similarly, response rates of 60% and 59% were observed in patients infected with noninvasive C. albicans and non-albicans Candida species, respectively. Compared with patients who received lower doses of ABLC, patients who required higher doses of ABLC because of more-virulent infections did not demonstrate significant renal impairment, as assessed by end-of-therapy changes in serum creatinine level from baseline (median, 0.1 mg/dL; range, -3.9 to 2.4 mg/dL), incidence of serum creatinine doubling (16%), and need for new dialysis (7%). These data indicate the safety and efficacy of ABLC in treating candidiasis.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/429330</identifier><identifier>PMID: 15809924</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Amphotericin B - therapeutic use ; Antifungal Agents - therapeutic use ; Antifungals ; Candida ; Candidemia ; Candidiasis ; Candidiasis - drug therapy ; Child ; Child, Preschool ; Dosage ; Drug Combinations ; Female ; Fungal infections ; Fungi ; Health outcomes ; Humans ; Infant ; Infections ; Lipids ; Lung diseases ; Male ; Medical treatment ; Middle Aged ; Patients ; Phosphatidylcholines - therapeutic use ; Phosphatidylglycerols - therapeutic use ; Registries ; Reproductive system ; Response rates ; Treatment Outcome</subject><ispartof>Clinical infectious diseases, 2005-05, Vol.40 (Supplement-6), p.S384-S391</ispartof><rights>Copyright 2005 The Infectious Diseases Society of America</rights><rights>Copyright University of Chicago, acting through its Press May 1, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-97b802a1d92fcb33d147c88a19c4e7dfe54ab65a02d2fc9f60776585f5bda8dc3</citedby><cites>FETCH-LOGICAL-c426t-97b802a1d92fcb33d147c88a19c4e7dfe54ab65a02d2fc9f60776585f5bda8dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4484195$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4484195$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27903,27904,57995,58228</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15809924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, James I.</creatorcontrib><creatorcontrib>Hooshmand-Rad, Roya</creatorcontrib><title>Treatment of Candida Infections with Amphotericin B Lipid Complex</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>The efficacy and renal safety of amphotericin B lipid complex (ABLC) were assessed in >900 patients with candidiasis. Overall, a favorable clinical response (cured or improved) was observed in 61% of patients infected with Candida species only, in 62% of patients infected with C. albicans, and in 61% of patients infected with a non-albicans Candida species. Clinical responses were similar in patients infected with invasive C. albicans and non-albicans Candida species (63% and 62%, respectively). Similarly, response rates of 60% and 59% were observed in patients infected with noninvasive C. albicans and non-albicans Candida species, respectively. Compared with patients who received lower doses of ABLC, patients who required higher doses of ABLC because of more-virulent infections did not demonstrate significant renal impairment, as assessed by end-of-therapy changes in serum creatinine level from baseline (median, 0.1 mg/dL; range, -3.9 to 2.4 mg/dL), incidence of serum creatinine doubling (16%), and need for new dialysis (7%). These data indicate the safety and efficacy of ABLC in treating candidiasis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amphotericin B - therapeutic use</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Antifungals</subject><subject>Candida</subject><subject>Candidemia</subject><subject>Candidiasis</subject><subject>Candidiasis - drug therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Dosage</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Fungal infections</subject><subject>Fungi</subject><subject>Health outcomes</subject><subject>Humans</subject><subject>Infant</subject><subject>Infections</subject><subject>Lipids</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Phosphatidylcholines - therapeutic use</subject><subject>Phosphatidylglycerols - therapeutic use</subject><subject>Registries</subject><subject>Reproductive system</subject><subject>Response rates</subject><subject>Treatment Outcome</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAYhIMofqz6C0SKB2_VpEma5LgWPxYWRFhRvIQ0STHrtqlJFtd_b2UXBS-e3oF5GN4ZAI4RvECQl5ekEBjDLbCPKGZ5SQXaHjSkPCcc8z1wEOMcQoQ4pLtgD1EOhSjIPhjPglWptV3KfJNVqjPOqGzSNVYn57uYfbj0mo3b_tUnG5x2XXaVTV3vTFb5tl_Y1SHYadQi2qPNHYHHm-tZdZdP728n1Xiaa1KUKRes5rBQyIii0TXGBhGmOVdIaGKZaSwlqi6pgoUZANGUkLGSctrQ2ihuNB6B83VuH_z70sYkWxe1XSxUZ_0yypIxiATF_4KIUcgFFQN49gec-2XohhKyQEIQTjn5TdPBxxhsI_vgWhU-JYLye3q5nn4ATzdpy7q15hfbbD0AJ2tgHpMPPz4hnHz_PQL52nYx2dWPrcLbUA0zKu-eXySpHm5Lip7lE_4Cl8OUQQ</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>Ito, James I.</creator><creator>Hooshmand-Rad, Roya</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>Treatment of Candida Infections with Amphotericin B Lipid Complex</title><author>Ito, James I. ; Hooshmand-Rad, Roya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-97b802a1d92fcb33d147c88a19c4e7dfe54ab65a02d2fc9f60776585f5bda8dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amphotericin B - therapeutic use</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Antifungals</topic><topic>Candida</topic><topic>Candidemia</topic><topic>Candidiasis</topic><topic>Candidiasis - drug therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Dosage</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Fungal infections</topic><topic>Fungi</topic><topic>Health outcomes</topic><topic>Humans</topic><topic>Infant</topic><topic>Infections</topic><topic>Lipids</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Phosphatidylcholines - therapeutic use</topic><topic>Phosphatidylglycerols - therapeutic use</topic><topic>Registries</topic><topic>Reproductive system</topic><topic>Response rates</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, James I.</creatorcontrib><creatorcontrib>Hooshmand-Rad, Roya</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, James I.</au><au>Hooshmand-Rad, Roya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Candida Infections with Amphotericin B Lipid Complex</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>40</volume><issue>Supplement-6</issue><spage>S384</spage><epage>S391</epage><pages>S384-S391</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>The efficacy and renal safety of amphotericin B lipid complex (ABLC) were assessed in >900 patients with candidiasis. Overall, a favorable clinical response (cured or improved) was observed in 61% of patients infected with Candida species only, in 62% of patients infected with C. albicans, and in 61% of patients infected with a non-albicans Candida species. Clinical responses were similar in patients infected with invasive C. albicans and non-albicans Candida species (63% and 62%, respectively). Similarly, response rates of 60% and 59% were observed in patients infected with noninvasive C. albicans and non-albicans Candida species, respectively. Compared with patients who received lower doses of ABLC, patients who required higher doses of ABLC because of more-virulent infections did not demonstrate significant renal impairment, as assessed by end-of-therapy changes in serum creatinine level from baseline (median, 0.1 mg/dL; range, -3.9 to 2.4 mg/dL), incidence of serum creatinine doubling (16%), and need for new dialysis (7%). These data indicate the safety and efficacy of ABLC in treating candidiasis.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>15809924</pmid><doi>10.1086/429330</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2005-05, Vol.40 (Supplement-6), p.S384-S391 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67701953 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Amphotericin B - therapeutic use Antifungal Agents - therapeutic use Antifungals Candida Candidemia Candidiasis Candidiasis - drug therapy Child Child, Preschool Dosage Drug Combinations Female Fungal infections Fungi Health outcomes Humans Infant Infections Lipids Lung diseases Male Medical treatment Middle Aged Patients Phosphatidylcholines - therapeutic use Phosphatidylglycerols - therapeutic use Registries Reproductive system Response rates Treatment Outcome |
| title | Treatment of Candida Infections with Amphotericin B Lipid Complex |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T15%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Candida%20Infections%20with%20Amphotericin%20B%20Lipid%20Complex&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Ito,%20James%20I.&rft.date=2005-05-01&rft.volume=40&rft.issue=Supplement-6&rft.spage=S384&rft.epage=S391&rft.pages=S384-S391&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/429330&rft_dat=%3Cjstor_proqu%3E4484195%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219948584&rft_id=info:pmid/15809924&rft_jstor_id=4484195&rfr_iscdi=true |